Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers

AIMS: The aim was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of octreotide subcutaneous (s.c.) depot, a novel octreotide formulation. METHODS: This was a phase I, randomized, open label study. After a single dose of octreotide immediate release (IR) 200 µg, subjects we...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiberg, Fredrik, Roberts, John, Cervin, Camilla, Johnsson, Markus, Sarp, Severine, Tripathi, Anadya Prakash, Linden, Margareta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574831/
https://www.ncbi.nlm.nih.gov/pubmed/26076191
http://dx.doi.org/10.1111/bcp.12698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574831/
https://www.ncbi.nlm.nih.gov/pubmed/26076191
http://dx.doi.org/10.1111/bcp.12698

Ejemplares similares